Parexel

Parexel International Corporation is an American biopharmaceutical services company headquartered in Waltham, Massachusetts, United States. Founded in 1982 by Josef von Rickenbach to assist with FDA approvals, it has become a leading contract research organization (CRO) through organic growth and over 40 acquisitions. Parexel operates through three segments: Clinical Research Services, providing Phase I-IV trial management; Consulting Services, offering regulatory and market access advice; and Informatics, delivering data management and eClinical solutions. The company maintains over 100 offices in more than 50 countries across North America, Europe, Asia, and Latin America, partnering with biotech firms and pharma giants for global trials while adhering to ICH-GCP, FDA, and EMA standards. It leverages AI for patient recruitment and real-world evidence generation. Acquired by EQT and Goldman Sachs in 2021 for $8.5 billion, Parexel emphasizes patient-centric innovation. In fiscal year 2024, Parexel contributed to EQT's revenues exceeding $3 billion in life sciences, with focus on oncology and rare diseases.